Trending NewsTrending NewsTop-Rated Dividend StocksTop-Rated DividendNYSE:ABT Abbott Laboratories (ABT) Stock Price, News & Analysis $104.00 +1.36 (+1.33%) As of 03:15 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Abbott Laboratories Stock (NYSE:ABT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abbott Laboratories alerts:Sign Up Key Stats Today's Range$103.00▼$104.6550-Day Range$96.62▼$116.7052-Week Range$81.97▼$132.02Volume3.84 million shsAverage Volume11.22 million shsMarket Capitalization$179.97 billionP/E Ratio38.77Dividend Yield2.42%Price Target$118.32Consensus RatingModerate Buy Company Overview Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world. Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care. The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte. Robert B. Ford serves as Abbott’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Abbott Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreABT MarketRank™: 4.27926766374 of 5 starsAbbott Laboratories scored higher than 86% of companies evaluated by MarketBeat, and ranked 45th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingAbbott Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 21 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialAbbott Laboratories has a consensus price target of $118.32, representing about 13.8% upside from its current price of $103.95.Amount of Analyst CoverageAbbott Laboratories has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Abbott Laboratories' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth7.79% Earnings GrowthEarnings for Abbott Laboratories are expected to grow by 7.79% in the coming year, from $5.52 to $5.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abbott Laboratories is 38.84, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.20.Price to Earnings Ratio vs. SectorThe P/E ratio of Abbott Laboratories is 38.84, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 37.20.Price to Earnings Growth RatioAbbott Laboratories has a PEG Ratio of 1.82. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAbbott Laboratories has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.01% of the float of Abbott Laboratories has been sold short.Short Interest Ratio / Days to CoverAbbott Laboratories has a short interest ratio ("days to cover") of 1.78, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abbott Laboratories has recently increased by 27.52%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAbbott Laboratories pays a meaningful dividend of 2.43%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAbbott Laboratories has been increasing its dividend for 54 years.Dividend CoverageThe dividend payout ratio of Abbott Laboratories is 94.03%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 42.35% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.Read more about Abbott Laboratories' dividend. News and Social Media3.3 / 5News Sentiment0.26 News SentimentAbbott Laboratories has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 66 news articles for Abbott Laboratories this week, compared to 10 articles on an average week.Search Interest53 people have searched for ABT on MarketBeat in the last 30 days. This is an increase of 23% compared to the previous 30 days.MarketBeat Follows30 people have added Abbott Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Abbott Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,958.00 in company stock.Percentage Held by Insiders0.46% of the stock of Abbott Laboratories is held by insiders.Percentage Held by Institutions75.18% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abbott Laboratories' insider trading history. Receive ABT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABT Stock News HeadlinesAbbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve diseaseOctober 29 at 9:00 AM | prnewswire.comAbbott Laboratories (NYSE:ABT) Stock Gets Downgrade from ArgusOctober 29 at 1:30 AM | americanbankingnews.comThree oil giants buried the same discovery for 50 yearsIn 1976, a Chevron drilling team tapped an energy source powerful enough to run a city, then buried the project. Unocal and Texaco confirmed the same results and shelved them too. One company spent 60 years perfecting the technology Big Oil walked away from. Google signed a 15-year contract, and Bill Gates wrote a 100 million dollar check. On November 17th, a new government policy hands this company an edge no other energy source receives.October 29 at 1:00 AM | Behind the Markets (Ad)Apple Stock And Other Quality Growth Names For Higher RatesOctober 28 at 7:55 PM | finance.yahoo.comMarketBeat Week in Review – 10/19 - 10/23 (ABT)A market sell-off spread beyond tech as oil prices surged and AI concerns grew. MarketBeat analysts recap the week's top stories on earnings, from Halliburton to Meta Platforms and General Motors.October 24, 2026 | marketbeat.com3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach (ABT)Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.October 23, 2026 | marketbeat.comCologuard Is Working—So Why Isn’t Abbott Stock?Abbott's stock fell 4% despite solid Q3 results, as it trimmed full-year sales guidance and announced plans to spin off its Nutrition business into a separate public company by 2027.October 22, 2026 | marketbeat.comCologuard Is Working—So Why Isn’t Abbott Stock?Abbott's stock fell 4% despite solid Q3 results, as it trimmed full-year sales guidance and announced plans to spin off its Nutrition business into a separate public company by 2027.October 22, 2026 | marketbeat.comSee More Headlines ABT Stock Analysis - Frequently Asked Questions How have ABT shares performed this year? Abbott Laboratories' stock was trading at $125.30 at the start of the year. Since then, ABT shares have decreased by 17.0% and is now trading at $103.9450. How were Abbott Laboratories' earnings last quarter? Abbott Laboratories (NYSE:ABT) posted its quarterly earnings data on Wednesday, October, 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting analysts' consensus estimates of $1.42. The business's revenue was up 14.5% compared to the same quarter last year. Read the conference call transcript. Does Abbott Laboratories have any subsidiaries? Abbott Laboratories subsidiaries include Cephea Valve Technologies, Alere, St. Jude Medical, Kalila Medical, Tendyne Holdings Inc., Veropharm, Topera Inc., and more. Who are Abbott Laboratories' major shareholders? Abbott Laboratories' top institutional investors include Assenagon Asset Management S.A. (0.30%), Sumitomo Mitsui Trust Group Inc. (0.21%), Mirae Asset Global Investments Co. Ltd. (0.11%) and ProShare Advisors LLC (0.11%). Insiders that own company stock include Daniel J Starks, Robert B Ford, Jr Robert E Funck, Jr Robert E Funck, Daniel Gesua Sive Salvadori, Mary K Moreland, Andrea F Wainer, Lisa D Earnhardt, Eric Shroff, Elizabeth C Cushman, John A Jr Mccoy and Philip P Boudreau. View institutional ownership trends. How do I buy shares of Abbott Laboratories? Shares of ABT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abbott Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abbott Laboratories investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Walmart (WMT), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD). Company Calendar Record date for 8/17 Dividend7/15/2026Ex-Dividend for 8/17 Dividend7/15/2026Dividend Payable8/17/2026Record date for 11/16 Dividend10/15/2026Ex-Dividend for 11/16 Dividend10/15/2026Last Earnings10/21/2026Today10/29/2026Dividend Payable11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 4 weeks, ABT's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:ABT CIK1800 Webwww.abbott.com Phone(224) 667-6100Fax847-937-1511Employees115,000Year Founded1888Price Target and Rating Average Price Target for Abbott Laboratories$118.32 High Price Target$135.00 Low Price Target$92.00 Potential Upside/Downside+14.0%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage28 Analysts Profitability EPS (Trailing Twelve Months)$2.68 Trailing P/E Ratio38.70 Forward P/E Ratio18.80 P/E Growth1.82Net Income$6.52 billion Net Margins9.75% Pretax Margin13.61% Return on Equity17.97% Return on Assets9.22% Debt Debt-to-Equity Ratio0.57 Current Ratio1.38 Quick Ratio0.97 Sales & Book Value Annual Sales$48.23 billion Price / Sales3.72 Cash Flow$7.00 per share Price / Cash Flow14.83 Book Value$30.35 per share Price / Book3.42Miscellaneous Outstanding Shares1,730,383,000Free Float1,722,423,000Market Cap$179.60 billion OptionableOptionable Beta0.59 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:ABT) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abbott Laboratories Please log in to your account or sign up in order to add this asset to your watchlist. Share Abbott Laboratories With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
